BR112014023859A8 - nanopartícula, composições, polipeptídeos isolados e purificados, métodos para preparar ou obter nanopartícula e para induzir resposta anti-inflamatória de célula ou tecido, para tratar inflamação, para acumular células t anti-inflamatórias e/ou células anti-inflamatórias no trato gastrointestinal de paciente necessitado do mesmo e para transferir linfócitos t citotóxicos e respectivos usos - Google Patents

nanopartícula, composições, polipeptídeos isolados e purificados, métodos para preparar ou obter nanopartícula e para induzir resposta anti-inflamatória de célula ou tecido, para tratar inflamação, para acumular células t anti-inflamatórias e/ou células anti-inflamatórias no trato gastrointestinal de paciente necessitado do mesmo e para transferir linfócitos t citotóxicos e respectivos usos

Info

Publication number
BR112014023859A8
BR112014023859A8 BR112014023859A BR112014023859A BR112014023859A8 BR 112014023859 A8 BR112014023859 A8 BR 112014023859A8 BR 112014023859 A BR112014023859 A BR 112014023859A BR 112014023859 A BR112014023859 A BR 112014023859A BR 112014023859 A8 BR112014023859 A8 BR 112014023859A8
Authority
BR
Brazil
Prior art keywords
inflammatory
nanoparticle
cells
lymphocytes
cytotoxic
Prior art date
Application number
BR112014023859A
Other languages
English (en)
Other versions
BR112014023859A2 (pt
BR112014023859B1 (pt
Inventor
Santamaria Pedro
Original Assignee
Uti Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uti Lp filed Critical Uti Lp
Publication of BR112014023859A2 publication Critical patent/BR112014023859A2/pt
Publication of BR112014023859A8 publication Critical patent/BR112014023859A8/pt
Publication of BR112014023859B1 publication Critical patent/BR112014023859B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0216Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112014023859-6A 2012-03-26 2013-03-25 Nanopartícula, uso da mesma, e composição BR112014023859B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615743P 2012-03-26 2012-03-26
US61/615,743 2012-03-26
PCT/IB2013/052352 WO2013144811A2 (en) 2012-03-26 2013-03-25 Methods and compositions for treating inflammation

Publications (3)

Publication Number Publication Date
BR112014023859A2 BR112014023859A2 (pt) 2017-07-18
BR112014023859A8 true BR112014023859A8 (pt) 2018-01-16
BR112014023859B1 BR112014023859B1 (pt) 2023-05-23

Family

ID=

Also Published As

Publication number Publication date
IL234829A0 (en) 2014-12-31
EP3590531A1 (en) 2020-01-08
IL269166A (en) 2019-11-28
US20210230237A1 (en) 2021-07-29
US20130330414A1 (en) 2013-12-12
ES2744491T3 (es) 2020-02-25
AU2013202911A1 (en) 2013-10-10
RU2689563C2 (ru) 2019-05-28
RU2014141984A (ru) 2016-05-20
AU2016203231A1 (en) 2016-06-09
EP2830654B1 (en) 2019-07-03
MX2014011623A (es) 2015-02-12
AU2016203231B2 (en) 2018-02-01
EP2830654B8 (en) 2019-08-07
EP2830654A2 (en) 2015-02-04
IL234829B (en) 2019-09-26
CA2868551A1 (en) 2013-10-03
CN110354278B (zh) 2023-05-02
BR112014023859A2 (pt) 2017-07-18
DK2830654T3 (da) 2019-08-26
JP6199955B2 (ja) 2017-09-20
MX363000B (es) 2019-03-01
US10988516B2 (en) 2021-04-27
WO2013144811A2 (en) 2013-10-03
JP2019108399A (ja) 2019-07-04
WO2013144811A3 (en) 2013-11-28
JP2015518467A (ja) 2015-07-02
PT2830654T (pt) 2019-09-23
CA2868551C (en) 2021-07-27
CN110354278A (zh) 2019-10-22
JP6570082B2 (ja) 2019-09-04
JP2018030842A (ja) 2018-03-01
PL2830654T3 (pl) 2020-02-28
CN104321077A (zh) 2015-01-28
HK1206641A1 (en) 2016-01-15

Similar Documents

Publication Publication Date Title
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
HK1208368A1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
CO6831973A2 (es) Composición inmunogénica para modulación del sistema inmune y su uso, método de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune
FR2986002B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
IL217490A (en) History of pyridine-4-il, pharmaceutical preparations containing them and their use in the preparation of medicines
FR2937972B1 (fr) Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
BR112012004154A2 (pt) "derivados de oxazina e seu uso no tratamento de distúrbios neurológicos"
FR2937973B1 (fr) Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
PL2576768T3 (pl) Oczyszczanie niehodowanych komórek macierzystych galarety Whartona
WO2013144811A3 (en) Methods and compositions for treating inflammation
FR2967674B1 (fr) Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
SG11201504447XA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
DK2365332T3 (da) HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
BR112014030953A2 (pt) "dispositivo de diagnóstico in vitro e usos"
SI2448940T1 (sl) Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba
WO2016040814A3 (en) Disulfide polymers and methods of use
EP3377622A4 (en) TARGETED DISTRIBUTION OF BIOVERCAPED THERAPEUTIC PROTEINS IN CROP CELLS TO CERTAIN CELL TYPES FOR THE TREATMENT OF DISEASES
FR2944794B1 (fr) Procede de preparation d'oligomeres de glycoside de flavonoide et utilisation en cosmetique.
EA201590732A1 (ru) Диспергируемая таблетка
HK1172568A1 (en) Soluble pharmaceutical forms of n,n-diaminodiphenyl sulphone for optimum use in the treatment of various diseases nn-
SG10201501606VA (en) Compounds, compositions, formulations and their uses in the treatment of diseases related to copper retention or hepatic disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.